🔗 Share this article

As America proceeds with sweeping revisions to its vaccine recommendations, an unexpected name has emerged in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by questioning coronavirus shots during the global health crisis and has zeroed in on possible deaths following Covid immunization in her recent tenure at the Food and Drug Administration.

Planned Changes to Childhood Vaccine Program

Health officials were set to announce major revisions to the childhood immunization program in December, aligning the US with Denmark’s national calendar, it is understood – a major change that would put the US out of step with a large portion of the world with insufficient data for benefit. This reveal has been postponed until the new year.

Instead of Vinay Prasad, Høeg is set to present at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the office this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the drug and biologics divisions as Høeg and Prasad consolidate power at the agency – and it signals a greater focus upon rolling back long-standing vaccines at the FDA.

Høeg has often pushed for halting specific pediatric vaccine recommendations in the US so as to align more similar to Denmark's approach, a society with comprehensive healthcare and a population approximately the size of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccines – usually the domain of Dr. Prasad, director of the FDA’s vaccine center – rather than medication approval.

Concerns Over Qualifications

The appointee has no obvious track record in drug development, regulation or administrative roles, which has been typical for previous directors of the CBER. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“She appears not to have any of the qualifications” for leading the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in managing a large organization. She lacks background in industry regulation.”

Past directors of the center would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that former directors who headed the center have had.”

This division has an vast range of responsibilities at the agency, the former commissioner pointed out.

“The public just zeroes in on the new drug program, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and so forth, and every single one have to be supervised,” Woodcock noted. “The responsibility you overlook, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial management component to the position, which oversees over 5,000 personnel. “It’s a huge leadership role, if you perform it correctly,” the former official concluded.

Agency Reaction and Disputed Programs

When asked about inquiries about Dr. Høeg's fitness for the role and whether this appointment represents increased cooperation among agency officials on vaccines, a representative responded that the “questions stem from incorrect premises”.

“Her experience matches the functions of her job,” the representative explained, noting the period Høeg spent advising the FDA commissioner on “drug safety and oversight research, including computational safety modeling and vaccine surveillance”.

In her interim role, Høeg inherits the agency head's new expedited review system, a disputed rapid drug-approval program that reportedly troubled her former heads. “How are these therapies being picked for this fast-track system? Who takes the choices?” Dr. Howard asked. “There is a lot of secrecy happening at the regulatory body right now.”

In general, he remarked, “the FDA looks to be trending towards less stringent regulations of most medications, except for shots.”

Public Past Work on Immunizations

Regarding immunizations, Dr. Høeg has a more established, if troubling, history, some experts observe. She authored a analysis using unconfirmed public submissions to assess the frequency of heart inflammation after COVID-19 immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccines are more dangerous than they are.

Part of her “desired changes” for the new government encompassed changing guidelines for novel immunizations and halting “non-essential” immunizations, she stated after the election on a audio program. At the agency, Dr. Høeg has allegedly suggested excluding young men from getting Covid vaccines.

“She is an all-around dogmatist who starts off with her beliefs and tailors the evidence to retrofit the evidence in a extremely disingenuous, dishonest fashion,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Høeg joined other contrarians, {like|